Does the laboratory evidence support the LDL-C comparison against the goal?
Example outputThe result sits just below the documented threshold, and supporting evidence raises uncertainty. Review the source-linked records.
CLINICAL EVIDENCE INTEGRITY
The evidence layer behind clinical decisions.
Does the evidence support your next decision?
GOVERN quietly gathers and evaluates the evidence behind clinical decisions. When lab results need a closer look, clinicians receive a clear explanation with supporting information, without disrupting their workflow. That same evidence helps support patient care, assess treatment response, and prepare documentation for medication access.
First clinical application: LDL-C threshold assessment · Clinicians remain in control.
SAME RECORDS, DIFFERENT QUESTIONS
The evidence carries forward.
Each decision gets its own check.
GOVERN keeps the evidence connected and checks it against the requirements of each task. An earlier assessment does not automatically carry forward with it.
Does the record contain the evidence this plan requires?
Example outputBaseline and follow-up results located. Treatment start date missing from available records. Requirements source: plan, policy version and effective date.
Illustrative examples. Statuses describe the records, not a clinical judgment or a coverage decision.
HOW IT WORKS
Evidence connected across every decision.
The same evidence that helps evaluate a lab result can be reused when treatment or insurance needs it. Records are gathered as needed for each authorized task, and additional documentation may still be required.
- 01
Understand the patient’s condition.
A laboratory result helps a clinician assess the patient’s treatment response.
Laboratory report · March 12 - 02
Know what the evidence supports.
GOVERN reviews the evidence and makes relevant limitations visible, without changing the result. It appears beside the result as a note: no pop-up, no required response.
Source-linked evidence note - 03
Support access to treatment.
When prior authorization is needed, the same source-linked evidence is checked against that plan’s requirements, which can differ from the clinical question.
In development
Illustrative · fictional patient
JD
Jane DoeSynthetic record · Laboratory report · March 12, 2026
Reused in packageClinical questionHas this patient reached their documented LDL-C goal?
| Test | Result | Reference / goal |
|---|---|---|
| Total cholesterol | 150 mg/dL | < 200 |
| HDL-C | 45 mg/dL | ≥ 40 |
| Triglycerides | 180 mg/dL H | < 150 |
| LDL-C | 69 mg/dL | Documented goal < 70 |
GOVERN · Evidence note
Reported LDL-C is 69 mg/dL, just below the documented threshold. Supporting laboratory evidence raises uncertainty about the below-goal classification. Further review may be warranted.
Reason for reviewMeasurement-method uncertainty near the documented threshold.
- Reported result: LDL-C 69 mg/dL, as released by the laboratory. GOVERN does not change it.
- Laboratory report (fictional record LP-017): total cholesterol 150, HDL-C 45 and triglycerides 180 mg/dL, collected Mar 12, 2026.
- Source records: laboratory report and accession record, linked for independent review.
- The clinician decides what, if anything, follows. This is an illustrative example.
Draft authorization evidence · example criterion · in development
Example criterionLDL-C reduced by at least 30% from baseline
Requirements source: Example Health Plan · Policy v3.2 · effective Jan 1, 2026
- Follow-up LDL-C: 69 mg/dLMarch 12 report, carried over from the evidence reviewReused
- Baseline LDL-C: 100 mg/dLEarlier report, Sept 4, 2025Located
- ?Reduction from baseline: 31%Calculated from the two reported values. The evidence note from step 2 still applies.Needs verification
- !Therapy start dateRequired by this policyMissing from available records
- Medication listCurrent lipid-lowering therapy on fileLocated
- Supporting source recordsLaboratory reports and accession recordsLocated
Criteria vary by payer and are shown here only as an example. Each status describes the records, not a payer’s decision or the patient’s clinical eligibility. People review the package before anything is submitted.
ONE EVIDENCE FOUNDATION
See what the evidence supports.
Every audience sees the same source-linked GOVERN evidence record. What changes is the question it answers. All patients, values and packets below are fictional illustrations of a product in development.
FOR PATIENTS
Your care deserves the full picture.
GOVERN helps your care team identify evidence that needs a closer look and organize the records needed to support treatment decisions and medication access.
So important information isn’t overlooked when your care depends on it.
One connected record of evidence
- Moment 1
When your doctor evaluates your treatment
GOVERN can bring attention to laboratory evidence that warrants closer review, helping your clinician understand what the results support.
- Moment 2
When you need access to medication
The same evidence can be combined with treatment records to help your care team prepare the documentation required for insurance review.
One connected record of evidence, supporting the next step in care.
CLINICIANS · EVIDENCE WITHOUT INTERRUPTIONS
Keep your workflow. Get the evidence behind the decision.
- The problem for you
- A result can be reported as below goal while the evidence behind it does not fully support that, and the chart shows only the result.
- How GOVERN helps
- A small note sits beside the result in the view you already use. Open it to see the supporting evidence, the original source records and the reason for review. The decision stays with you.
- In practice
- Select the note in the example, then copy the draft wording into a chart note or patient message.
Illustrative · fictional patient
Total cholesterol150mg/dL
HDL45mg/dL
Triglycerides180 Hmg/dL
LDL-C Goal < 7069mg/dL
- Why review: Reported LDL-C is 69 mg/dL, just below the documented threshold. Supporting laboratory evidence raises uncertainty about the below-goal classification. Further review may be warranted.
- Source records: lipid panel components with collection time, linked to the original laboratory report.
Draft wording
LDL-C 69 mg/dL, reported as below the documented goal. GOVERN evidence note: supporting laboratory evidence raises uncertainty about the below-goal classification; further review may be warranted. Source records linked.
MEDICATION ACCESS TEAMS · EVIDENCE READY FOR AUTHORIZATION
Spend less time searching for evidence. More time helping patients access treatment.
- The problem for you
- Prior authorization needs prior LDL-C results, baseline-to-follow-up comparisons and treatment history, scattered across records.
- How GOVERN helps
- It can gather those records once and check them against a payer’s stated requirements, recording which policy version applied. Source links and missing items are visible before anything is sent.
- In practice
- A draft evidence packet, in which every line points to its source or says what is missing.
Illustrative · draft packet · planned capability
Draft evidence packet fictional patient · example criteria
Requirements source: Example Health Plan · Policy v3.2 · effective Jan 1, 2026
- Baseline LDL-CResult on file · source linkedLocated
- Follow-up LDL-CResult on file · source linkedLocated
- Baseline-to-follow-up changeComputed from the two results aboveNeeds verification
- Treatment historyMedication list · source linkedLocated
- Documentation of prior therapy attemptsRequired by this policyMissing from available records
Nothing is submitted until a person reviews the packet.
PAYERS · EVIDENCE THAT CAN BE REVIEWED
Clearer evidence. More consistent reviews.
- The problem for you
- Requests arrive with evidence that is hard to trace and gaps that are hard to see.
- How GOVERN helps
- Source-linked results, treatment documentation and explicit evidence gaps could make requests easier to assess. The coverage decision stays with the payer.
Illustrative · planned capability
Evidence summary by requirement
| Requirement | Evidence |
|---|---|
| LDL-C result | Located · source linked |
| Treatment history | Located · source linked |
| Baseline-to-follow-up change | Needs verification |
| Prior therapy attempts | Missing from available records |
Shows what supports each requirement. Missing documentation is not a coverage denial, and the table does not recommend approval or denial.
Illustrations show intended functionality of a product in development. Not yet demonstrated clinical or economic outcomes; integrations are planned.
THE CLINICAL QUESTION
One lipid panel can put LDL-C on both sides of 70 mg/dL.
Near a threshold, the calculation method can change how the same panel is classified. Here is a simple example—and what retrospective research found.
Illustrative lipid panelSame sample
Total cholesterol150mg/dL
HDL-C45mg/dL
Triglycerides180mg/dL
Friedewald69mg/dL · below 70
Threshold70mg/dL
Sampson/NIH75mg/dL · above 70
Illustrative calculations from the same panel. They show a threshold disagreement, not which estimate is closer to the reference value.
In selected panels, equation disagreement tracked lower comparator agreement.
Across 11,182 panels, the equations agreed on which side of 70 mg/dL the result fell in 85.7% of cases.
94.6%When equations agreed, classification matched the routine comparator.
60.6%When they disagreed, the majority-vote classification matched it.
The comparator was a routine direct-designated LDL-C result, not beta-quantification. This finding suggests disagreement can signal uncertainty; it does not establish which method was correct or prove GOVERN works.
PRODUCT PILOT PARTNERSHIPS
Bring us the clinical question
your team needs answered.
See how GOVERN fits your clinical workflow. Laboratory and informatics teams help bring it into your health system.
Discuss a clinical pilot Start with a conversation. No patient data required.